Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand Disease
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Grifols
- 04 Jul 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 04 Jul 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 04 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.